Literature DB >> 7543395

Endothelium-dependent relaxation of small arteries from essential hypertensive patients: mechanisms and comparison with normotensive subjects and with responses of vessels from spontaneously hypertensive rats.

L Y Deng1, J S Li, E L Schiffrin.   

Abstract

1. Impaired endothelium-dependent relaxation has been previously demonstrated in blood vessels of hypertensive rats and in humans with essential hypertension. Arteries from spontaneously hypertensive rats have been shown to produce, in response to high concentrations of acetylcholine, a vasoconstrictor substance called endothelium-derived contracting factor, the production of which can be inhibited by indomethacin or other cyclo-oxygenase inhibitors, suggesting that it is a prostanoid. The mechanisms involved in endothelium-dependent relaxation of human arteries are unclear, and the potential generation of endothelium-derived contracting factor by endothelium in human hypertension has not been established. 2. We investigated the effects of acetylcholine on precontracted small arteries dissected from gluteal subcutaneous fat biopsies from normotensive subjects and subjects with borderline and mild essential hypertension. Vessels from normotensive subjects and those from borderline hypertensive patients, precontracted by noradrenaline, were relaxed completely by acetylcholine, whereas those from patients with mild essential hypertension relaxed slightly but significantly less, indicating that generation of endothelium-derived relaxing factor (endothelium-derived nitric oxide) was only minimally reduced or that production of minor amounts of endothelium-derived contracting factor occurred in small arteries from these hypertensive subjects. This impairment of endothelium-dependent relaxation was not corrected by indomethacin, which indicated that the contribution of endothelium-derived contracting factor, if any, was minimal in this subset of essential hypertensive patients. In contrast, mesenteric small arteries of adult spontaneously hypertensive rats presented strong contractions in response to the higher concentrations of acetylcholine, which were abolished by exposure to indomethacin. 3. The relaxation induced by acetylcholine in arteries from both hypertensive and normotensive humans was partially blunted (by 30%) by pretreatment with 0.1 mmol/l NG-nitro-L-arginine methyl ester or NG-nitro-monomethyl-L-arginine (inhibitors of nitric oxide synthase) and by 10 mumol/l Methylene Blue (a blocker of soluble guanylate cyclase), indicating the role of endothelium-derived nitric oxide and the generation of its intracellular second messenger cyclic guanosine monophosphate in acetylcholine-induced relaxation. The remaining relaxation elicited by acetylcholine could be blocked with 30 mmol/l KCl or with 10 mumol/l ouabain (inhibitor of Na+, K(+)-ATPase), and, when combined with NG-nitro-L-arginine methyl ester, these interventions abolished acetylcholine-induced relaxation. Tolbutamide at 2 mmol/l or 10 mumol/l glyburide (blockers of ATP-sensitive potassium channels) partially inhibited NG-nitro-L-arginine methyl ester-resistant endothelium-dependent relaxation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543395     DOI: 10.1042/cs0880611

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  14 in total

Review 1.  Small artery remodelling in hypertension: causes, consequences and therapeutic implications.

Authors:  Michael J Mulvany
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

2.  Systemic vascular endothelial cell dysfunction in normal pressure glaucoma.

Authors:  Christine Buckley; Patrick W F Hadoke; Emer Henry; Colm O'Brien
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

3.  Enhanced endothelium derived hyperpolarising factor activity in resistance arteries from normal pressure glaucoma patients: implications for vascular function in the eye.

Authors:  C Cleary; C H Buckley; E Henry; P McLoughlin; C O'Brien; P W F Hadoke
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

4.  Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease.

Authors:  P J Smith; C J Ferro; D S McQueen; D J Webb
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

5.  Endothelium-derived hyperpolarizing factor and potassium use different mechanisms to induce relaxation of human subcutaneous resistance arteries.

Authors:  C A McIntyre; C H Buckley; G C Jones; T C Sandeep; R C Andrews; A I Elliott; G A Gray; B C Williams; J A McKnight; B R Walker; P W Hadoke
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 6.  Effects of antihypertensive therapy on hypertensive vascular disease.

Authors:  J B Park; E L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

7.  Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries.

Authors:  I F Pascoal; M D Lindheimer; C Nalbantian-Brandt; J G Umans
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

8.  Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries.

Authors:  N H Buus; U Simonsen; H K Pilegaard; M J Mulvany
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

9.  Autonomic Blockade Reverses Endothelial Dysfunction in Obesity-Associated Hypertension.

Authors:  Alfredo Gamboa; Rocío Figueroa; Sachin Y Paranjape; Ginnie Farley; Andre Diedrich; Italo Biaggioni
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

10.  NO-induced vasodilation correlates directly with BP in smooth muscle-Na/Ca exchanger-1-engineered mice: elevated BP does not attenuate endothelial function.

Authors:  Youhua Wang; Jin Zhang; W Gil Wier; Ling Chen; Mordecai P Blaustein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-30       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.